PART I — FINANCIAL INFORMATION This part presents the unaudited condensed consolidated financial statements and management's discussion and analysis [ITEM 1. FINANCIAL STATEMENTS](index=3&type=section&id=ITEM%201.%20FINANCIAL%20STATEMENTS) This section presents the unaudited condensed consolidated financial statements and notes for Q1 2021 [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This section presents the company's financial position, detailing assets, liabilities, and shareholders' equity at specific dates Balance Sheet Items | ASSETS/LIABILITIES | March 31, 2021 (in thousands) | December 31, 2020 (in thousands) | | :----------------- | :---------------------------- | :------------------------------- | | Cash and cash equivalents | $61,033 | $20,786 | | Total current assets | $124,069 | $94,254 | | Total assets | $325,424 | $303,274 | | Total current liabilities | $109,090 | $132,686 | | Total liabilities | $220,121 | $247,760 | | Shareholders' Equity | $105,303 | $55,514 | - Total assets **increased by $22.15 million** from December 31, 2020, to March 31, 2021, primarily driven by a **significant increase in cash and cash equivalents**[7](index=7&type=chunk) - Total liabilities **decreased by $27.64 million**, mainly due to a reduction in current liabilities, particularly accrued rebates, returns, and discounts, and accrued liabilities[7](index=7&type=chunk) [Condensed Consolidated Statements of Comprehensive Income](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Income) This section reports the company's revenues, expenses, and net income over specific periods Comprehensive Income Metrics | Metric | Three Months Ended March 31, 2021 (in thousands) | Three Months Ended March 31, 2020 (in thousands) | | :-------------------------------- | :----------------------------------------------- | :----------------------------------------------- | | Total revenues | $26,839 | $20,917 | | Total costs and expenses | $19,332 | $37,549 | | Income (Loss) from operations | $7,507 | $(16,632) | | Total other (expense) income | $(2,415) | $59,910 | | Net income and Comprehensive income | $4,544 | $41,230 | | Basic net income per share | $0.03 | $0.51 | | Diluted net income per share | $0.03 | $0.51 | - Total revenues **increased by $5.92 million** (**28.3%**) year-over-year, primarily driven by product sales from newly acquired INDOCIN and SPRIX products[10](index=10&type=chunk) - The company **swung from an operating loss of $16.63 million** in Q1 2020 to an **operating income of $7.51 million** in Q1 2021, largely due to reduced selling, general and administrative expenses[10](index=10&type=chunk) - Net income **decreased significantly** from **$41.23 million** in Q1 2020 to **$4.54 million** in Q1 2021, mainly due to a large one-time gain on the sale of Gralise in the prior year[10](index=10&type=chunk) [Condensed Consolidated Statements of Shareholders' Equity](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Shareholders'%20Equity) This section details changes in the company's equity accounts, including common stock and retained earnings Shareholders' Equity Summary | Metric | December 31, 2020 (in thousands) | March 31, 2021 (in thousands) | | :-------------------------------- | :------------------------------- | :---------------------------- | | Common Shares (in thousands) | 113,569 | 173,744 | | Stock Amount (in thousands) | $13 | $18 | | Additional Paid-In Capital (in thousands) | $483,446 | $528,686 | | Accumulated Earnings (Deficit) (in thousands) | $(427,945) | $(423,401) | | Shareholders' Equity (in thousands) | $55,514 | $105,303 | - Shareholders' equity **increased by $49.79 million** from December 31, 2020, to March 31, 2021, primarily driven by the issuance of common stock in connection with stock offerings (**$44.86 million**) and net income (**$4.54 million**)[13](index=13&type=chunk) - Common shares outstanding **increased significantly** from **113,569 thousand** to **173,744 thousand**, largely due to the issuance of **57,600 thousand** shares in stock offerings[13](index=13&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This section summarizes cash inflows and outflows from operating, investing, and financing activities Cash Flow Summary | Cash Flow Activity | Three Months Ended March 31, 2021 (in thousands) | Three Months Ended March 31, 2020 (in thousands) | | :-------------------------------- | :----------------------------------------------- | :----------------------------------------------- | | Net cash used in operating activities | $(4,226) | $(25,063) | | Net cash provided by investing activities | — | $449,036 | | Net cash provided by (used in) financing activities | $44,473 | $(360,107) | | Net increase in cash and cash equivalents | $40,247 | $63,866 | | Cash and cash equivalents at end of period | $61,033 | $105,973 | - Net cash used in operating activities **decreased significantly** from **$25.06 million** in Q1 2020 to **$4.23 million** in Q1 2021, primarily due to the prior year's divestitures of Gralise and NUCYNTA[17](index=17&type=chunk)[135](index=135&type=chunk) - Net cash provided by financing activities was **$44.47 million** in Q1 2021, a **substantial increase** from the **$360.11 million** used in Q1 2020, driven by proceeds from registered direct stock offerings in February 2021[17](index=17&type=chunk)[137](index=137&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements, including the balance sheets, statements of comprehensive income, statements of shareholders' equity, and statements of cash flows, along with detailed notes explaining significant accounting policies, revenue breakdown, asset and liability components, debt, equity, and commitments for the quarter ended March 31, 2021 [NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES](index=7&type=section&id=NOTE%201.%20SUMMARY%20OF%20SIGNIFICANT%20ACCOUNTING%20POLICIES) This note outlines significant accounting policies, SEC compliance, and the impact of COVID-19 on company operations - The company adapted to COVID-19 by initiating remote work and increasing virtual visits with providers due to limitations on in-person interactions[23](index=23&type=chunk) - COVID-19 led to a decline in prescriptions associated with elective surgeries, impacting the company's product sales[23](index=23&type=chunk) [NOTE 2. REVENUE](index=7&type=section&id=NOTE%202.%20REVENUE) This note disaggregates Q1 2021 and 2020 revenue by type, highlighting Zyla Merger product sales and NUCYNTA divestiture impacts Revenue Breakdown by Type | Revenue Type | Three Months Ended March 31, 2021 (in thousands) | Three Months Ended March 31, 2020 (in thousands) | | :-------------------------------- | :----------------------------------------------- | :----------------------------------------------- | | Product sales, net | $26,405 | $9,252 | | Commercialization agreement, net | — | $11,258 | | Royalties and milestones | $434 | $407 | | Total revenues | $26,839 | $20,917 | - Product sales, net, **increased significantly** to **$26.41 million** in Q1 2021 from **$9.25 million** in Q1 2020, primarily due to the acquisition of INDOCIN Products (**$14.60 million**) and SPRIX (**$1.70 million**) from the Zyla Merger in May 2020[26](index=26&type=chunk)[27](index=27&type=chunk) - Commercialization agreement revenue **ceased** in Q1 2021, compared to **$11.26 million** in Q1 2020, following the sale of the NUCYNTA franchise in February 2020[26](index=26&type=chunk)[29](index=29&type=chunk) [NOTE 3. ACCOUNTS RECEIVABLES, NET](index=9&type=section&id=NOTE%203.%20ACCOUNTS%20RECEIVABLES,%20NET) This note details the components of accounts receivable, net, as of March 31, 2021, and December 31,

Study Objective and Design - The ZENITH20 study is a Phase 2, open-label, multi-cohort, multi-center trial evaluating poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations[3] - Cohort 5 of ZENITH20 randomizes patients to different arms with varying doses of poziotinib: 10, 12, and 16 mg QD or 6 and 8 mg BID[3] Safety and Tolerability - Poziotinib demonstrates improved tolerability with BID dosing compared to QD dosing at both 8mg and 6mg BID[16] - The incidence of ≥Grade 3 related Adverse Events (AEs) was lower in the 8mg BID group (26%) compared to the 16mg QD group (50%)[8] - Drug interruption was less frequent in the 6mg BID group (50%) compared to the 16mg QD group (82%)[9] - Dose reduction was less frequent in the 10mg QD group (34%) compared to the 16mg QD group (59%)[9] Efficacy - Preliminary response data suggests improved anti-tumor activity with 8mg BID dosing compared to 10, 12, 16mg QD or 6mg BID[17] - The Overall Response Rate (ORR) in the 8mg BID group was 316% compared to 158% in the 16mg QD and 12mg QD groups, and 53% in the 6mg BID and 10mg QD groups[10] - The Disease Control Rate (DCR) in the 8mg BID group was 684% compared to 526% in the 16mg QD group[10]

Spectrum Pharmaceuticals, Inc. (SPPI) Q4 2020 Earnings Conference Call March 30, 2021 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Joe Turgeon - President and CEO Dr. François Lebel - Chief Medical Officer Tom Riga - Chief Operating Officer Conference Call Participants Maury Raycroft - Jefferies Emilia Falcetti - Cantor Fitzgerald Ed White - H.C. Wainwright Sahil Kazmi - B. Riley Securities Reni Benjamin - JMP Securities Operator Ladies and gentlemen, thank you for standing by. A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-39294 ASSERTIO HOLDINGS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 85-0598378 (STATE OR OTHER JURISDICTION O ...

Assertio Holdings, Inc. (NASDAQ:ASRT) Q3 2020 Earnings Conference Call November 6, 2020 8:30 AM ET Company Participants Lee Roth - Burns McClellan Todd Smith - President, CEO and Director Dan Peisert - Chief Financial Officer Mark Strobeck - Chief Operating Officer Conference Call Participants Scott Henry - ROTH Capital Sally Yanchus - Brookline Capital Kevin Kedra - G.research Operator Good morning, ladies and gentleman, and welcome to the Quarter Three 2020 Assertio Therapeutics Incorporated Earnings Conf ...

Spectrum Pharmaceuticals, Inc. (SPPI) Q2 2020 Earnings Conference Call August 10, 2020 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Joe Turgeon - President & Chief Executive Officer François Lebel - Chief Medical Officer Tom Riga - Chief Operating Officer Conference Call Participants Maury Raycroft - Jefferies Li Watsek - Cantor Ed White - H.C. Wainwright Michael Schmidt - Guggenheim Sahil Kazmi - B. Riley FBR Operator Good afternoon ladies and gentlemen and welcome to the Spectr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-39294 ASSERTIO HOLDINGS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 85-0598378 (STATE OR OTHER JURISDICTION OF INC ...